Reviewing Fractyl Health (GUTS) and Its Peers

Fractyl Health (NASDAQ:GUTS) is one of 236 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its rivals? We will compare Fractyl Health to related businesses based on the strength of its earnings, analyst recommendations, institutional ownership, risk, profitability, valuation and dividends.

Profitability

This table compares Fractyl Health and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fractyl Health	-64,849.48%	N/A	-57.21%
Fractyl Health Competitors	-574.62%	-156.70%	-27.31%

Institutional & Insider Ownership

47.9% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 15.5% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Fractyl Health and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Fractyl Health	$120,000.00	-$77.09 million	-0.19
Fractyl Health Competitors	$1.03 billion	$10.63 million	-6.55

Fractyl Health’s rivals have higher revenue and earnings than Fractyl Health. Fractyl Health is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Fractyl Health and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fractyl Health	0	0	3	0	3.00
Fractyl Health Competitors	1914	4910	9146	268	2.48

Fractyl Health currently has a consensus price target of $22.00, indicating a potential upside of 869.16%. As a group, “Surgical & medical instruments” companies have a potential upside of 15.56%. Given Fractyl Health’s stronger consensus rating and higher probable upside, analysts plainly believe Fractyl Health is more favorable than its rivals.

Summary

Fractyl Health rivals beat Fractyl Health on 7 of the 12 factors compared.

About Fractyl Health

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.